We use cookies to ensure our site functions properly and to store limited information about your usage. You may give or withdraw consent at any time. To find out more, read our privacy policy and cookie policy.
Manage Cookies
A cookie is information stored on your computer by a website you visit. Cookies often store your settings for a website, such as your preferred language or location. This allows the site to present you with information customized to fit your needs. As per the GDPR law, companies need to get your explicit approval to collect your data. Some of these cookies are ‘strictly necessary’ to provide the basic functions of the website and can not be turned off, while others if present, have the option of being turned off. Learn more about our Privacy and Cookie policies. These can be managed also from our cookie policy page.
Strictly necessary cookies(always on):
Necessary for enabling core functionality. The website cannot function properly without these cookies. This cannot be turned off. e.g. Sign in, Language
Analytics cookies:
Analytical cookies help us to analyse user behaviour, mainly to see if the users are able to find and act on things that they are looking for. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. Tools used: Google Analytics
Canadian Blood Services is responsible for securing and providing plasma protein and related products (PPRP) to hospitals across Canada for use by clinicians and their patients in all provinces and territories (except Quebec). Currently, patients using products at home generally pick up their supply from the hospital and then administer the treatment at home.
Canadian Blood Services is piloting a program for home delivery to eligible patients in Alberta using Bayshore Pharmacy, a specialty pharmacy. The purpose of this pilot is to demonstrate that this is a feasible option for providing home care PPRP to patients, while increasing Canadian Blood Services’ access to product use data. Getting data from Bayshore Pharmacy on the use of PPRP will allow Canadian Blood Services to better manage PPRP access, demand planning, and inventory management.
Canadian Blood Services is responsible for securing and providing plasma protein and related products (PPRP) to hospitals across Canada for use by clinicians and their patients in all provinces and territories (except Quebec). Currently, patients using products at home generally pick up their supply from the hospital and then administer the treatment at home.
Canadian Blood Services is piloting a program for home delivery to eligible patients in Alberta using Bayshore Pharmacy, a specialty pharmacy. The purpose of this pilot is to demonstrate that this is a feasible option for providing home care PPRP to patients, while increasing Canadian Blood Services’ access to product use data. Getting data from Bayshore Pharmacy on the use of PPRP will allow Canadian Blood Services to better manage PPRP access, demand planning, and inventory management.
You are receiving this survey because you are involved in the care of patients receiving Hemlibra (emicizumab) and/or Glassia (alpha-1 proteinase inhibitor) through the Distribution Modernization (DM) project in Alberta. This survey is being done to evaluate DM and provide Canadian Blood Services with important information about clinic and hospital customers’ experiences to further improve the project. This feedback will also be included in a report to the Ministry of Health to help inform decisions on continuation of this project.
The DM project at Canadian Blood Services was started in October 2023 and currently involves delivery of Hemlibra and Glassia by Bayshore Pharmacy to patients in Alberta (most often to their homes). In addition to dispensing and delivering medications, Bayshore Pharmacy coordinates with patients’ medical providers, patient support programs, and Canadian Blood Services to make sure patients have the medications and supplies they need. The project provides Canadian Blood Services with dispensing data to help us better understand how these products are being used, and ensure patients have access to the best possible care.
Please note that this survey is only evaluating the Distribution Modernization project, with services provided by Bayshore Pharmacy. Patient support programs (e.g., OnePath, EasySTART, Innomar) are not being evaluated in this survey.
The survey should take you 10-15 minutes to complete and will be open until March 16, 2025. Thank you for participating and sharing your view with us.
You are receiving this survey because you are either a patient or a caregiver of a patient receiving Hemlibra (emicizumab) or Glassia (alpha-1 proteinase inhibitor) through the Distribution Modernization (DM) project in Alberta. This survey is being done to evaluate DM and provide Canadian Blood Services with important information to further improve the project. This feedback will also be included in a report to the Ministry of Health to help inform decisions on continuation of this project.
The DM project at Canadian Blood Services was started in October 2023 and currently involves delivery of Hemlibra and Glassia by Bayshore Pharmacy to patients in Alberta (most often to their homes). In addition to dispensing and delivering medications, Bayshore Pharmacy coordinates with patients’ medical providers, patient support programs, and Canadian Blood Services to make sure patients have the medications and supplies they need. The project provides valuable information about how these medications are being used, which helps Canadian Blood Services support patient access to the best possible care.
Please note that this survey is only evaluating the Distribution Modernization project, with services provided by Bayshore Pharmacy. Patient support programs (e.g., OnePath, EasySTART, Innomar) are not being evaluated in this survey.
The survey should take you 10-15 minutes to complete and will be open until March 16, 2025. Thank you for participating and sharing your view with us.